178 related articles for article (PubMed ID: 37060883)
21. Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas.
Rajendran M; Rao M; Elhence PA; Bharti JN; Singh P; Yadav G; Nalwa A; Goyal AD
J Midlife Health; 2023; 14(2):81-86. PubMed ID: 38029026
[TBL] [Abstract][Full Text] [Related]
22. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
24. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
25. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
[TBL] [Abstract][Full Text] [Related]
28. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
Front Immunol; 2021; 12():561793. PubMed ID: 33717059
[TBL] [Abstract][Full Text] [Related]
29. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S
Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949
[TBL] [Abstract][Full Text] [Related]
30. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
33. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract][Full Text] [Related]
35. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
39. CD169
Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
[TBL] [Abstract][Full Text] [Related]
40. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
